Drug Profile
Izencitinib - Theravance Biopharma
Alternative Names: JNJ-8398; TD 1473Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Theravance Biopharma
- Developer Mayo Clinic; Theravance Biopharma
- Class Amines; Anti-inflammatories; Azabicyclo compounds; Gastrokinetics; Naphthyridines; Nitriles; Pyrazoles; Small molecules
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Diabetic gastroparesis; Inflammatory bowel diseases; Ulcerative colitis